Table 1.
Association between EpCAM expression and clinicopathological parameters
| Clinicopathological parameters | EpCAM positive | EpCAM negative | P value | ||
|---|---|---|---|---|---|
| Mean age at diagnosis (years) | 52.59 | 10.66% | 50.63 | 11.49% | <0.388 |
| Tumor grade | <0.446 | ||||
| I | 0 | 0.00% | 2 | 3.64% | |
| II | 24 | 57.14% | 29 | 52.73% | |
| III | 18 | 42.86% | 24 | 43.64% | |
| Tumor Stage | <0.276 | ||||
| I | 10 | 23.81% | 7 | 12.73% | |
| II | 23 | 54,76% | 38 | 69.09% | |
| III | 9 | 21.43% | 10 | 18.18% | |
| Size | <0.402 | ||||
| <2 cm | 11 | 26.19% | 9 | 15.79% | |
| 2-5 cm | 29 | 69.05% | 46 | 80.70% | |
| ≥5 cm | 2 | 4.76% | 2 | 3.51% | |
| Estrogen receptor | <0.002 | ||||
| ER+ | 9 | 21.43% | 30 | 51.72% | |
| ER- | 33 | 78.57% | 28 | 48.28% | |
| Progesterone receptor | <0.006 | ||||
| PR+ | 9 | 21.43% | 28 | 28.48% | |
| PR- | 33 | 78.57% | 30 | 51.72% | |
| HER2 | <0.198 | ||||
| HER2+ | 10 | 23.81% | 8 | 13.79% | |
| HER2- | 32 | 76.19% | 50 | 86.21% | |
| Ki67 | <0.658 | ||||
| <14% | 6 | 14.29% | 10 | 17.24% | |
| 14-29% | 5 | 11.90% | 10 | 17.24% | |
| ≥30% | 31 | 73.81% | 38 | 65.52% | |
| LVI | <0.892 | ||||
| N1 | 33 | 78.57% | 47 | 81.03% | |
| N2 | 5 | 11.90% | 7 | 12.07% | |
| N3 | 4 | 9.52% | 4 | 6.90% | |
| TNBC | <0.073 | ||||
| TNBC+ | 25 | 59.52% | 24 | 41.38% | |
| TNBC- | 17 | 40.48% | 34 | 58.62% | |
| Met/Recurrence | <0.002 | ||||
| Yes | 13 | 30.95% | 4 | 7.14% | |
| No | 29 | 69.05% | 52 | 92.86% | |
Abbreviations: EpCAM = epithelial cell adhesion molecule; ER = estrogen receptor; HER2 = human epidermal growth factor receptor; LVI = lymph vascular invasion; TNBC = Triple Negative Breast Cancer.